Introduction
Atopic dermatitis is a chronic inflammatory disease which results from complex interactions between genetic and environmental mechanisms. [1] [2] [3] [4] [5] [6] Atopic dermatitis afflicts 10-15% of children and adolescents in the Western world. Keratinocytes of patients with atopic dermatitis exhibit a propensity to exaggerated production of cytokines and chemokines, a phenomenon that can have a major role in promoting and maintaining inflammation. The primary reaction is a Th1 reaction and it is now thought that a Th2 response is mediated via high affinity IgE receptors on Langerhans cells. Of pivotal importance in the persistence of atopic eczema is the stimulation of the immune systems by superantigens produced by Staphylococcus aureus. Specific immune responses against a variety of environmental allergens are also implicated in the pathogenesis of atopic dermatitis. Cross-linkage of specific IgE receptors on dermal mast cells provokes the release and synthesis of a vast series of mediators. Following their recruitment into the skin and activation, eosinophils are also thought to contribute significantly to tissue damage. Thus, a complex network of cytokines and chemokines contributes to establishing a local milieu that favors the permanence of inflammation in the skin of atopic dermatitis. Recent progress in molecular biology has provided new insights into the pathophysiology of atopic dermatitis. Numerous cytokines related to atopic dermatitis seem to be regulated by certain transcription factors. In particular, NF-kB is the center of interest, since it promotes the transcription of Th2 cytokines, such as IL-6 as well as adhesion molecules such as ICAM-1. 7, 8 In addition, the delayed allergic component of atopic dermatitis, dependent on the Th1-dominant pathway, is also believed to be regulated by NF-kB-induced cytokines such as IFN-r. Therefore, in this study, we focused on the role of NF-kB in the pathogenesis of atopic dermatitis.
Recently, the decoy strategy has been developed and considered a useful tool as a new class of anti-gene strategy.
9,10 Transfection of double-stranded oligodeoxynucleotides (ODN) as a decoy corresponding to the cis sequence results in attenuation of the authentic cis-trans interaction, leading to the removal of trans-factors from the endogenous cis-element, with subsequent modulation of gene expression. 9, 10 Therefore, the decoy approach enables us to treat diseases by modulating endogenous transcriptional regulation. [11] [12] [13] [14] [15] We hypothesized that the skin's allergic response in atopic dermatitis might be improved by the transfection of NF-kB decoy ODN. If the expression of cytokines and adhesion molecules involved in the development of atopic skin conditions, the most important step in the process of atopic dermatitis might be suppressed by NF-kB decoy ODN in vivo. This study demonstrated that topical delivery of NF-kB decoy ODN into atopic dermatitis skin in NC/Nga mice resulted in a significant improvement. Since side-effects can limit the clinical usefulness of corticosteroids, topically applied NF-kB decoy ODN appears to provide novel therapeutic potency without significant local or adverse effects.
Results
Feasibility of transfection of NF-kB decoy ODN using ointment into the skin First, we examined whether NF-kB decoy ODN in ointment might penetrate deep into the skin through the epidermis. FITC-labeled NF-kB decoy ODN were applied to the neck of 8-week-old SPF male NC/Nga mice which had no atopic dermatitis at this time point. As shown in Figure 1 , topical application of FITC-labeled decoy ODN resulted in the accumulation of fluorescence deep in the skin, including in keratinocytes and more in dermal infiltrated cells and cells comprising hair follicles at 1 day after transfection. Localization of ODN in the nuclei was confirmed by the observation that fluorescence due to FITC-labeled ODN co-existed in the red color due to PI staining ( Figure 1a) . The fluorescence was continued up to at least 4 days after transfection, and disappeared within 1 week after transfection. In contrast, little fluorescence was observed in the neck of NC/Nga mice trans- 
Clinical and pathological comparison of atopic dermatitis lesions
To examine the therapeutic effects of NF-kB decoy ODN, we used NC/Nga mice (NC mice) which show atopic dermatitis-like skin lesions with aging, as a possible model for atopic dermatitis. [16] [17] [18] The skin lesions of inbred NC mice are clinically and histologically very similar to those of human atopic dermatitis when the mice are raised under conventional conditions, but not under SPF conditions. Skin lesions spontaneously appear on the face, neck, ears and dorsal skin of inbred NC/Nga mice in non-sterile (conventional) conditions. Given the successful transfection of NF-kB decoy ODN, we applied either NF-kB decoy ODN or scrambled decoy ODN using ointment to the ears, head, neck and rostral part of the back. First, we examined the effects of NF-kB decoy ODN on the progression of atopic dermatitis by topical application from 12 to 20 weeks of age twice a month. The atopic dermatitis-like lesions of mice transfected with NF-kB decoy ODN demonstrated a significant improvement in clinical skin scores as compared with mice transfected with scrambled decoy ODN (P Ͻ 0.01, Figures 2a  and 3 ). There was no significant difference in clinical skin scores between mice transfected with scrambled decoy ODN and mice treated with vehicle in ointment. Improvement of clinical skin condition by NF-kB decoy ODN was also confirmed by the observation that the lesions of mice transfected with NF-kB decoy ODN showed amelioration of hyperkeratosis, acanthosis, and hypergranulosis in hematoxylin and eosin (H&E)-stained sections at 20 weeks as compared with mice transfected with scrambled decoy ODN ( Figure 4 ). In addition, the control mice exhibited marked spongiosis and infiltration of cells. Moreover, as previously reported, 16, 17 immunohistochemical examination of the skin lesions showed an increase in the number of mast cells containing IL-4 which are necessary for IgE synthesis. Interestingly, the number of infiltrated mast cells was significantly decreased in the dermis of mice transfected with NF-kB decoy ODN as compared with mice transfected with scrambled decoy ODN in toluidine blue (TB)-stained sections ( Figure 5 , scrambled decoy ODN: 16.0 ± 2.3 cells/field, NFkB decoy ODN: 1.8 ± 0.7 cells/field, P Ͻ 0.01). These data suggest that the highly increased turnover of basal cells and marked spongiosis recovered to normal by the treatment with NF-kB decoy ODN. Probably, the decrease in infiltrated mast cells might be responsible for the prevention of atopic dermatitis.
Next, we examined the effects of NF-kB decoy ODN on the regression of atopic dermatitis, to consider their clinical usage. We confirmed that the macroscopic lesions of atopic dermatitis were significantly improved in mice transfected with NF-kB decoy ODN, as compared with mice transfected with scrambled decoy ODN (P Ͻ 0.01, Figures 6a and 7) . In HE-stained sections, atopic dermatitis lesions of mice transfected with NF-kB decoy ODN were also improved, since features such as hyperkeratosis, acanthosis, and hypergranulosis were clearly improved ( Figure 8 ). In TB-stained sections, infiltrated mast cells were also decreased in mice transfected with NF-kB decoy ODN ( P Ͻ 0.01), similar to the prevention study ( Figure 5 ). Regression of atopic dermatitis lesions by NF-kB decoy ODN was further confirmed by the observation that the improvement of skin lesions was limited to the area transfected with NF-kB decoy ODN. As shown in Figure  9 , in NC/Nga mice, the lesions of atopic dermatitis progressed from the anterior part (head and neck) toward the posterior part waist, as the lower back was far beyond the reach of scratching by the legs. In mice transfected with scrambled decoy ODN, an atopic dermatitis-like skin condition developed from anterior to posterior, consistent with the findings in untransfected mice. In contrast, anterior lesions transfected with NF-kB decoy ODN were markedly improved as compared with untransfected posterior lesions. More importantly, the decrease in the number of infiltrated mast cells by NF-kB decoy ODN was partially due to the induction of apoptosis, since these cells were stained by TUNEL staining using serial sections at 3 days and 1 week after transfection ( Figure 10 ). We observed that most of the apoptotic cells were identical to anti-CD117-positive mast cells using double immunostaining (Figure 11) . Probably, the dermal Gene Therapy apoptotic cells in mast cells induced by NF-kB decoy ODN might contribute to the marked amelioration of atopic dermatitis. Finally, to clarify the specificity of NFkB decoy ODN, we performed the immunohistochemial staining against ICAM, since ICAM is a well-known molecule driven by NFkB. As shown in Figure 12 , transfection of NFkB decoy ODN significantly inhibited expression of ICAM-positive cells as compared with scrambled decoy ODN (P Ͻ 0.01, scrambled decoy ODN: 57.2 ± 9.3 cells/field, NFkB decoy ODN: 17.0 ± 3.9 cells/field). These studies documented that transfection of NFkB decoy ODN blocked the induction of NFkBdriven gene expression in a sequence-specific manner.
Discussion
The decoy strategy using double-stranded ODN corresponding to the cis sequence has been recently developed as a new class of anti-gene strategy. 9, 0 In the present study, we investigated the anti-inflammatory effect of NF-kB decoy ODN on atopic dermatitis-like skin in NC mice, to understand the role of the transcription factor NF-kB in the pathogenesis of atopic dermatitis. First, we investigated the feasibility of topical delivery of decoy ODN using ointment containing FITC-labeled decoy ODN. Fluorescence was readily detected in the epidermis and dermis, and fluorescence was detected in the dermis for at least 4 days after a single transfection. The present study suggests that expression of targeted genes in targeted organs such as the epidermis can be regulated by topical transfection of decoy ODN in ointment in mice, consistent with a previous report. 19 These findings encouraged us to investigate the potential utility of NFkB decoy ODN for the treatment of the skin symptoms observed in atopic dermatitis in a mouse model.
In NC/Nga mice, atopic dermatitis begins with skin scratching 8 weeks after birth when mice are raised in conventional rearing conditions. Atopic dermatitis lesions first appear on the head and back of the neck at 10 weeks, spread to the back and ears at 11 weeks, spread over the whole body at 13 weeks, and reach a plateau at 17 weeks after birth. Immunohistochemical examination of atopic dermatitis lesions in conventional NC/Nga mice showed the typical features of affected skin observed in human atopic dermatitis patients, such as an increased number of mast cells with marked degranulation. Most NC/Nga mice have more skin eruptions on their neck than other body parts due to Mycoptes musculinus (Kekuidani). 18 Considering this fact, we topically applied NF-kB decoy ODN to the neck of mice with dermatitis as a typical atopic dermatitis lesion from 12 to 20 weeks, twice a month. The present study clearly demonstrated that topically applied NF-kB decoy ODN The dermal apoptotic cells were identified as anti-CD117-positive dermal mast cells. We believe, particularly, that the decrease in the number of the infiltrated mast cells is important, since the previous paper demonstrated that the suppression of mast cells activation is pivotal for the therapeutic effects of glucocorticoid. 21 Looking toward clinical usage, we also examined the resolution of atopic dermatitis by NF-kB decoy ODN treatment. It is noteworthy that a single topical delivery of NF-kB decoy ODN significantly regressed atopic dermatitis. Interestingly, the therapeutic effects of NF-kB decoy ODN seem to be local, since the serum level of IgE was not affected by application of NF-kB decoy ODN ointment (data not shown). As mentioned above, activation of the transcription factor NF-kB transactivated targeted genes such as IL-1␤, -8, -12, -18, TNF-␣, ICAM-1, VCAM-1, and MCP-1, to name a few, responsible for atopic dermatitis. The present study demonstrated an important role of the transcription factor, NF-kB, in the development of the skin lesions of atopic dermatitis. The importance of these cytokines in atopic dermatitis was confirmed by the observation that corticosteroids and tacrolimus (FK-506) inhibit NF-kB activation. 22, 23 In addition to the decrease in inflammatory cytokines, the improvement of dysregulated apoptosis in skin-homing cells may also contribute to the development and persistence of atopic dermatitis. 24 More recently, the importance of NFkB was proved by the observation that IkB␣ deficiency resulted in a sustained NF-kB response and severe widespread dermatitis in mice. 25 In addition, the skin of RelBdeficient mice develops T cell-dependent skin lesions similar to human atopic dermatitis, 26 correlating with induced p50-RelA/NF-kB activity due to IkB␣ stability. 27 These reports support the efficacy of NF-kB decoy ODN to treat atopic dermatitis.
Figure 6 Macroscopic appearance of mice treated with NF-kB decoy ODN ointment at 1 week after transfection. The mice were transfected with NFkB decoy ODN by a single topical administration. Neck (a) and face (b) of mice transfected with scrambled decoy ODN; Neck (c) and face (d) of mice transfected with NF-kB decoy ODN.

Figure 7 Regression of atopic dermatitis-like skin by NF-kB decoy ODN as assessed by clinical skin condition scores. NF-kB decoy, mice transfected with NF-kB decoy
What is the clinical relevalence of NF-kB decoy ODN? Currently, the pharmaceutical drugs that can be used to treat atopic dermatitis are limited. Despite the rapid and proven efficacy of topical corticosteroids, their sideeffects limit their clinical usefulness. Topically active macrolide immunosuppressants, such as ascomycin and tacrolimus appear to provide comparable therapeutic potency. 22, 23 Although the data from ongoing studies will be crucial in determining the safety of these agents in the long term, and also their place within the current therapeutic armamentarium available for patients with atopic dermatitis, these agents still have potential side-effects, such as systemic absorption. In contrast, NF-kB decoy ODN only exert local pharmacological effects for the following reasons: (1) ODN in serum were rapidly destroyed (within several hours), leading to a lack of systemic effects.
28 ( 2) The toxicity of systemic administration of ODN was only reported at over 100-fold higher concentration than that employed in the present study. 29 Indeed, serum IgE level was not affected by topical administration of NF-kB decoy ODN. Overall, NF-kB decoy ODN via topical application should be considered as an alternative treatment to inhibit the progression and 
Figure 9 Limited inhibitory effects of NF-kB decoy ODN on skin transfected with ODN. Rostral back (a) and caudal back (c) of mice transfected with scrambled decoy ODN; Rostral back (b) and caudal back (d) of mice transfected with NF-kB decoy ODN. Regression of atopic dermatitis skin by NFkB decoy ODN was limited to the rostral back (only topically applied lesions).
cause regression of atopic dermatitis, although further studies are necessary, especially to answer the potential long-term side-effects such as cutaneous infection or carcinogenesis due to local immunosuppression. transcription factor. [11] [12] [13] [14] [15] 30 Synthetic ODN were washed with 70% ethanol, dried and dissolved in sterile Tris-EDTA buffer (10 mM Tris, 1 mM EDTA). The supernatant was purified over a NAP 10 column (Pharmacia, Uppsala, Sweden), and quantitated by spectrophotometry. ODN were synthesized by Hokkaido System Science (Sapporo, Japan). FITC was used to label the 3' and 5'-ends of NF-kB decoy ODN. For topical application, 10 mg of either NF-kB ODN or scrambled decoy ODN was mixed with 0.6 g petrolatum-based ointment, containing 5% stearyl alcohol. In this study, we formulated ODN ointment with stearyl alcohol for emulsion. The ointments were stored at 4°C until use.
Materials and methods
Synthesis of ODN and selection of target sequences
In vivo transfer of FITC-labeled ODN
Transfer of FITC-labeled ODN was performed according to the following protocols: (1) 2 mg of ointment containing FITC-labeled phosphorothioate decoy ODN, and (2) 2 mg of ointment without FITC-labeled phosphorothioate decoy ODN. Four days after transfection, mice were killed, and tissues were removed after perfusion-fixation with 4% paraformaldehyde. Sections were examined by fluorescent microscopy, after staining in erichrome black T solution. Elastic fibers stained dark red were readily distinguishable from the specific FITC-labeled ODN after treatment with erichrome black T solution (data not shown). 31, 32 In vivo topical application of NF-kB ODN ointment on atopic dermatitis skin lesions in NC/Nga atopic mouse model SPF male, 4 weeks old, NC/Nga mice were purchased from SLC (Hamamatsu, Japan). These were bred and housed under conventional conditions in the Hamaguchi Animal Center (Kawanishi, Japan). Mice that had dermatitis were chosen at random. The mice were classified in four study groups: (1) ointment containing NF-kB decoy ODN; (2) ointment containing scrambled decoy ODN; (3) ointment without ODN; (4) no treatment. To examine the effects of NF-kB decoy ODN on the progression of atopic dermatitis, ointment was applied from 12 to 20 weeks to mice that had mild skin signs. A dose of 2 mg ODN per head was applied to the skin of the ears, head and anterior back every 2 weeks. To examine the effects on the regression of atopic dermatitis, ointment was applied from 29 to 30 weeks to mice that had severe skin signs. A dose of 2 mg ODN was used once at 29 weeks. The severity of atopic dermatitis was assessed with the following clinical skin condition score. Signs were evaluated from two standpoints evaluated by five signs and symptoms (eruption; edema and erosion/excoriation: exudate/wound; itch, erythema/hemorrhage and scaling/dryness). 16 The whole body was divided into the following three parts; ears, face, head and back. Each sign was graded from 0 to 3 (no sign, 0; slight, 0.5; mild, 1; moderate, 2; and severe, 3). Clinical skin condition score was defined as the sum of the points, ranging from 0 to 18. 6 The animals were coded so that analysis was performed without any knowledge of which treatment each individual animal had received. Intra-observer variability was determined from triplicate measurements performed by one observer for all sections. The mean ± s.d. difference among measurements made by the same observer was 2.8 ± 0.2%. Inter-observer variability was determined from measurements of 10 randomly selected sections performed by a second observer in addition to the first. The numerical difference between the measurements made by the two observers was 1.4 ± 0.4%. These observers were blinded to other data concerning the mice, as well as to the results of the other observer. Blood was taken once a month from the inferior vena cava and serum IgE was measured by an enzyme immunoassay with mAb (SRL, Osaka, Japan). Tissue samples were evaluated and compared with respect to macroscopic appearance, clinical skin condition scores, and HE and TUNEL-stained sections.
Histology
Tissue samples of the skin from the neck of each animal were fixed in 10% neutral-buffered formalin solution overnight and embedded in paraffin by the conventional method, cut into 5 m-thick sections, and stained with HE or toluidine blue (TB) for mast cells. The numbers of mast cells were counted and compared with the atopic dermatitis lesions among the four groups. The animals were coded so that analysis was performed without any knowledge of which treatment each individual animal had received.
TUNEL staining
Sections from between four and six animals (for each group) were deparaffinized, rehydrated, treated with proteinase K (20 g/ml), and incubated with PBS containing 0.3% hydrogen peroxide to reduce endogenous peroxidase activity. The method for nick end-labeling of apoptotic cells was adapted from that of Gavrieli et al 33 using a commercial ApopTag Plus Fluorescein In Situ Apoptosis Detection Kit (Intergen, Purchase, NY, USA). It is based on the preferential binding of digoxigenindUTP by TUNEL, and then detected by an antidigoxigenin antibody conjugated with peroxidase, a reporter enzyme that catalytically generates a brown-colored product from the chromogenic substrate diaminobenzidine (DAB). Counterstaining was performed by immersing the slides in 0.5% methyl green in 0.1 M sodium acetate solution (pH 4.0) for 5 min at room temperature.
Double immunostaining
A piece of fresh skin from the dorsal neck of each animal was stored at Ϫ80°C until use and embedded in OCT compound (Miles, Elkhart, IN, USA). Frozen sections, cut in 5 m-thick slices, were stored at Ϫ80°C until use (SRL, Osaka, Japan). The tissue sections were fixed in acetone for 30 min. After washing with 1 × PBS, they were stained with TUNEL staining according to the manufacturer's directions in the ApopTag Plus Fluorescein In Situ Apoptosis Detection Kit (Intergen). PE-conjugated rat monoclonal antibodies against CD117 purchased from Pharmingen (San Diego, CA, USA) were applied for 2 h in PBS at a dilution of 1:10. After washing with PBS, immunostaining of the tissue sections was evaluated using a Nikon Eclipse TE 300/200 microscope at ×100, ×200 and ×400 magnification in a blinded manner.
Statistical analysis
All values are expressed as mean ± s.e.m. Analysis of variance with subsequent Duncan's test was used to determine the significance of differences in multiple comparisons. Differences with a P value less than 0.05 were considered significant.
